Lee Ainslie Intercept Pharmaceuticals, Inc. Transaction History

Maverick Capital LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$14.28 - $19.53 $40,369 - $55,211	-2,827 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$12.99 - $20.47 $601,086 - $947,208	-46,273 Reduced 94.24%	2,827 $42,000
Q2 2021 Aug 16, 2021	BUY	$15.46 - $24.5 $187,576 - $297,258	12,133 Added 32.82%	49,100 $981,000
Q1 2021 May 17, 2021	BUY	$19.33 - $37.75 $400,614 - $782,368	20,725 Added 127.6%	36,967 $853,000
Q4 2020 Feb 16, 2021	BUY	$24.48 - $42.47 $397,604 - $689,797	16,242 New	16,242 $401,000

1.04M

30K

5.9K

Ticker ICPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,127,400
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination wit...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.